TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03864926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus XR
Description: Envarsus XR is FDA approved for the prophylaxis of organ rejection in kidney transplant recipients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants. Envarsus XR, is designed to deliver tacrolimus more smoothly over the whole day.~Envarsus XR, a calcineurin-inhibitor immunosuppressant, is available for oral administration as extended-release tablets containing the equivalent of 0.75 mg, 1 mg, or 4 mg of anhydrous tacrolimus USP. Inactive ingredients include hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF. Tacrolimus is the active ingredient in ENVARSUS XR.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus (generic; immediate release) is FDA approved for the prophylaxis of organ rejection in heart, kidney and liver transplant recipients.
Study: NCT04193163

Intervention type: DEVICE
Intervention: Hip prosthesis - ESOP 2 cementless femoral stem
Description: ESOP 2 femoral stems are intended to be implanted in the femoral region during total hip arthroplasty in order to restore joint function.
Study: NCT01960621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclodextrin
Description: intravenous
Study: NCT01653548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habituation Reminder Training
Description: Participants will hear a unique sound after habituating to a personal stressor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habituation Reminder Training
Description: Participants will hear a unique sound after habituating to a personal stressor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habituation Reminder
Description: Participants will hear the habituation reminder outside of the lab via a cellular phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habituation
Description: Participants will habituate to personally-relevant stressor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habituation
Description: Participants will habituate to personally-relevant stressor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habituation
Description: Participants will habituate to personally-relevant stressor.
Study: NCT02562456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART using Fuji IX
Description: Occlusal and occlusoproximal ART restorations in primary molars using the high viscosity GIC Fuji IX will be performed under relative isolation. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked. For occlusoproximal restoration, an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Occlusal and occlusoproximal composite resin restorations in primary molars using the Scotchbond Multi-purpose adhesive system and the Filtek Z-350 composite resin wil be performed. Local anesthesia will be used. Absolute isolation will be performed using rubber dam and clamp. Removal of unsupported enamel will be performed using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched using 37% phosphoric acid for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked. an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
Study: NCT01697514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680
Description: Capsule administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680
Description: Powder administered orally (may be sprinkled on soft food).
Study: NCT03894930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metta meditation
Description: Administered 5 days per week for 8 weeks.
Study: NCT02469285

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified pork
Description: Pork with modified fatty acid composition

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pork
Description: Pork with normal fat composition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pork and berries
Description: Pork with normal fat composition and Finnish berries
Study: NCT00500084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: Administered orally
Study: NCT04057274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise assessment
Description: The moderate-intensity aerobic interval exercise will be performed on a cycle ergometer under the supervision of trained staff in an exercise science laboratory. Participants will perform a 5 to 10-minute warm-up that begins by pedalling against a light resistance (60 W) and progressively increases in resistance until a target heart rate of 50-60% heart rate reserve is achieved. Participants will then complete 6 x 5-minute bouts at 60% heart rate reserve whilst maintaining a cadence of 60 rev·min-1, separated by 2.5-minutes of pedalling against light resistance (60 W). The session will finish with a cool-down at light resistance (60 W) lasting 10-minutes.
Study: NCT03439865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 mg tablet PO BID x 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard of care treatment
Description: topical nasal steroid spray and culture-directed antibiotics x 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care treatment
Description: topical nasal steroid spray and culture-directed antibiotics x 14 days
Study: NCT00704782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimebon
Study: NCT03203239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red Light (670 nm energy)
Description: Light Emitting Diode light source (670 nm wavelength with output up to 75mW/cm2) will be placed over the gastrocnemius muscle. The light will be on for 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octafluoropropane
Description: All subjects will undergo infusion of octafluoropropane to measure peripheral blood flow.
Study: NCT03887897

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal Intubation
Description: Tracheal intubation performed by attending anesthesiologists using either Airtraq laryngoscope or Macintosh laryngoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal Intubation
Description: Tracheal intubation performed by attending anesthesiologists using either Airtraq laryngoscope or Macintosh laryngoscope
Study: NCT02500524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocamide diethanolamine
Description: Topical lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin
Description: Topical creme rinse
Study: NCT03452592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alflutinib
Description: Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg
Study: NCT00183274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Description: Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Description: Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Description: Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: six month intervention with placebo drug
Study: NCT01697514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680
Description: Powder administered orally (may be sprinkled on soft food).
Study: NCT02756416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI brain
Description: Standard MRI brain will be performed on each participant to look at brain structure and exclude complications of RCVS (if any).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASL-MRI brain
Description: ASL-MRI is a non-contrast scan used to measure cortical cerebral blood flow (CBF) in areas supplied by major arteries (Circle of Willis).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRA brain
Description: MR angiography scan looks at blood vessels structure. We expect to see constriction (narrowing) of the major arteries in RCVS cases.
Study: NCT00183274

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: six month intervention with placebo drug
Study: NCT03017235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution
Description: Supplied as two 160 mL ready-to-drink bottles, per subject, without further reconstitution, before administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder
Description: Supplied as two sachets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
Study: NCT02327624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Compare Clopidogrel to two doses of Ticagrelor 60 and 90

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60
Description: Compare Clopidogrel to two doses of Ticagrelor 60 and 90

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90
Description: Compare Clopidogrel to two doses of Ticagrelor 60 and 90
Study: NCT01538654

Intervention type: PROCEDURE
Intervention: enteral protein tube feeding in obese
Description: The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding
Study: NCT02214238

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP device
Study: NCT00581113

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Treatments are delivered through parallel opposed or 5 degree RAO/LAO fields that cover the entire cranial contents. There should be beam fall-f of at least 1 cm. The eyes must be excluded from the beam either by field arrangement or shielding.
Study: NCT04499261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: Patients were supine in a reverse Trendelenburg position and received intravenous inhalation combined with anesthesia. The patients' legs were spread apart. A carbon dioxide pneumoperitoneum was established. The intermittent Pringle's maneuver was carried out when necessary. Five trocars were placed in a fan shape around the lesion. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Patients were placed in the supine position and received intravenous inhalation combined with anesthesia. The intermittent Pringle's maneuver was carried out when necessary. Routinely, a reversed L-shape incision was performed. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.
Study: NCT01604265

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Contained delta-9-tetrahydrocannabinol (THC), (25 mg/ml):cannabidiol (CBD), (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
Study: NCT01578733

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein intake.
Description: •Protein intakes will be varied at 0.2, 0.5, 0.7, 0.9,1.0, 1.2, 1.5, 1.8g, 2.0g/kg/day
Study: NCT04363775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The standard Macintosh laryngoscope
Description: intubation with the standard Macintosh laryngoscope and endotracheal tube 7.0 internal diameter with standard tube stylet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The standard Macintosh laryngoscope
Description: intubation with the standard Macintosh laryngoscope and endotracheal tube 7.0 internal diameter with standard tube stylet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Vie Scope laryngoscope
Description: intubation with the Vie Scope laryngoscope with bougie stylet and endotracheal tube 7.0 internal diameter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Vie Scope laryngoscope
Description: intubation with the Vie Scope laryngoscope with bougie stylet and endotracheal tube 7.0 internal diameter
Study: NCT04242082

Intervention type: DIAGNOSTIC_TEST
Intervention: GLUT 1 gene expression
Description: GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.~Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: GLUT 1 gene expression
Description: GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.~Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: GLUT 1 gene expression
Description: GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.~Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment.
Study: NCT04213612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin, cyclophosphamide, vincristine,
Description: PLD 40mg/m2 ; PLD 50mg/m2 ; PLD 60mg/m2 ; Maximum tolerated dose； Dose-limiting toxicity
Study: NCT00199862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine-124 labeled humanized A33 (antibody)
Description: Patients will receive a single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes. On study days 2, 3, and/or 4 patients will have the option to receive up to 2g/kg of IVIG. Patients will be evaluated with 124I-huA33 positron-emission tomography (PET) with ex vivo quantitation of tumor uptake.
Study: NCT02776488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Lactate
Description: Infusion of exogenous sodium lactate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of normal saline
Study: NCT00464334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V950
Description: V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V950
Description: V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V950
Description: V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V950
Description: V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V950
Description: V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V950
Description: V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V950
Description: V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V950
Description: V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V950
Description: V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISCOMATRIX™
Description: ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISCOMATRIX™
Description: ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISCOMATRIX™
Description: ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISCOMATRIX™
Description: ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISCOMATRIX™
Description: ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISCOMATRIX™
Description: ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISCOMATRIX™
Description: ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISCOMATRIX™
Description: ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.
Study: NCT02871908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Description: Lactobacillus reuteri DSM 17938 twice daily 2 x 10\^8

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06201806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test food breakfast with NCS or witout NCS
Description: Study Intervention: 30 drops (70.8 mg) of a stevia and sucralose mix were chosen based on Ford et al. 2011, indicating a 48 mg sucralose concentration comparable to the sweetness of a standard diet soda, due to a lack of studies on the acute effects of combined non-nutritive sweeteners.~Glycemic Responses (GR): Blood samples collected using Accu-Chek® Instant glucometer, with fasting samples establishing baseline glucose concentration. Test breakfast or white bread consumed within 12 to 15 minutes, followed by capillary blood sampling at various intervals. Continuous glucose monitoring with a sensor was also implemented.~Glycemic Index (GI) Calculation: Geometric calculation of the area under the curve (AUC) for each food, excluding the baseline area. Test breakfast GI determined by expressing AUC as a percentage of the standard food AUC. Final GI value averaged across groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test food breakfast with NCS or witout NCS
Description: Study Intervention: 30 drops (70.8 mg) of a stevia and sucralose mix were chosen based on Ford et al. 2011, indicating a 48 mg sucralose concentration comparable to the sweetness of a standard diet soda, due to a lack of studies on the acute effects of combined non-nutritive sweeteners.~Glycemic Responses (GR): Blood samples collected using Accu-Chek® Instant glucometer, with fasting samples establishing baseline glucose concentration. Test breakfast or white bread consumed within 12 to 15 minutes, followed by capillary blood sampling at various intervals. Continuous glucose monitoring with a sensor was also implemented.~Glycemic Index (GI) Calculation: Geometric calculation of the area under the curve (AUC) for each food, excluding the baseline area. Test breakfast GI determined by expressing AUC as a percentage of the standard food AUC. Final GI value averaged across groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test food breakfast with NCS or witout NCS
Description: Study Intervention: 30 drops (70.8 mg) of a stevia and sucralose mix were chosen based on Ford et al. 2011, indicating a 48 mg sucralose concentration comparable to the sweetness of a standard diet soda, due to a lack of studies on the acute effects of combined non-nutritive sweeteners.~Glycemic Responses (GR): Blood samples collected using Accu-Chek® Instant glucometer, with fasting samples establishing baseline glucose concentration. Test breakfast or white bread consumed within 12 to 15 minutes, followed by capillary blood sampling at various intervals. Continuous glucose monitoring with a sensor was also implemented.~Glycemic Index (GI) Calculation: Geometric calculation of the area under the curve (AUC) for each food, excluding the baseline area. Test breakfast GI determined by expressing AUC as a percentage of the standard food AUC. Final GI value averaged across groups.